News|Podcasts|March 12, 2026

Moving CAR-T Beyond Oncology

Vincent Hennemand discusses using these types of therapies to develop treatments for autoimmune conditions.

Sail Biomedicine’s chief products and operations officer joined the Pharmaceutical Executive Podcast to discuss how researchers are developing CAR-T therapies that go beyond oncology. According to him, recent advancements have provided researchers with significant results using CAR-T to treat autoimmune conditions, such as lupus or rheumatoid arthritis.

  • Hennemand explains the historical context of cell-based therapies in oncology, noting their success but limitations due to high costs and logistical challenges.
  • Hennemand explains that Sail started in oncology but quickly pivoted to autoimmune disorders due to the suitability of RNA-based CAR T therapies.
  • Hennemand highlights the advantages of RNA technology, such as quick expression and fast repopulation, which make it ideal for autoimmune disorders.
  • Hennemand mentions that Sail’s closest competitors also started in oncology but have since shifted their focus to autoimmune disorders.

Related to this article

Pharmaceutical Executive Daily
FDA reportedly shelves its Commissioner’s National Priority Voucher program, Eli Lilly breaks ground on a $3.5 billion Pennsylvania manufacturing site for next-generation obesity treatments, and Parexel’s Stacy Hurt on how small protocol decisions can become enrollment and retention barriers.
Pharmaceutical Executive Daily
FDA approves Merck KGaA’s Pimjetmi for tenosynovial giant cell tumor, Parexel’s Stacy Hurt on when patient input should enter the clinical research process, and Ignite Proteomics’ Dr. Brian Corgiat on adjusting for tumor mutations in treatment decisions.
Pharmaceutical Executive daily
argenx acquires Unnatural Products for up to $1.15 billion to expand its immunology capabilities, GiftHealth’s Chip Parkinson on how single-partner platforms can transform the prescription journey, and Partha Anbil on why competing on net value matters more than cutting list prices as US drug pricing resets.